Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

  • This share is currently suspended. It was suspended at a price of 5.375

Share Price Information for Iconic Labs (ICON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.375
ICON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Name Change to Iconic Labs Plc and Results of GM

10 Jul 2019 15:59

RNS Number : 1400F
WideCells Group PLC
10 July 2019
 

10 July 2019

Iconic Labs Plc ("Iconic Labs" or the "Company")

Results of GM - Change of Name to Iconic Labs Plc

 

The Board is pleased to announce that the Company has changed its name to Iconic Labs Plc ('Iconic Labs') to reflect its new focus as a multi-divisional new media and technology business. This change takes effect following the Company's General Meeting ("GM") held today, where all resolutions were duly passed. The new ticker for the Company will be ICON and take effect on 11 July 2019.

 

Iconic Labs provides online marketing, content and technology driven products to enable companies to increase their consumer engagement and build brand presence. The team, led by John Quinlan and Liam Harrington, who were founders and key drivers behind UNILAD, the world's largest social media publisher, is making progress with regards to its new media activities, highlighted by the recently announced consulting and marketing services engagement with a UK-based financial services business, where work has commenced. 

 

The progress made has been achieved with just a soft launch; an official launch is planned, which the Company believes will benefit client acquisitions and brand awareness in the sector. The Board anticipates that the name change will be beneficial to securing new business opportunities, attracting potential complementary acquisitions as well as creating increased visibility for investors. 

 

Iconic Labs operates in a rapidly growing market driven by consumer habits shifting to digital and social from TV and print, increasing numbers of distribution platforms fighting for premium content to attract audiences, and traditional agencies struggling to adapt to client demands and new technologies. As an example, global mobile ad spend is projected to increase from US$138 billion in 2018 to US$212 billion in 2021, while Subscription Video On Demand services rose from 14% of households in 2014 to 39% in 2018. The market is fragmented, and the Board believes that, by utilising its contact base, experience of growing new media businesses and sector knowledge, it can take advantage of this fast-developing market.

 

With regards to the WideCells business, the Board continues to address legacy issues and the cash involved and will inform the market when these have been resolved. It is obviously frustrating for both the management and shareholders that there remain outstanding issues, but the Board is working to alleviate these and ensure that the new business has a firm platform that can be utilised for the benefit of all stakeholders. 

 

The Board looks forward to updating shareholders as it implements its defined growth strategy both organically and via targeted value-accretive acquisitions utilising its platform and paper.

 

Chief Executive Officer, John Quinlan, said: "I'm delighted that the name change to Iconic Labs has been effected as the name reflects the current direction of the business in the new media space. We have a proven track record in the delivery of advice, strategic planning, content provision and developing technology, primarily garnered from our time at UNILAD, which achieved revenues in excess of £10 million per annum; we are utilising this experience to build a business. There is a distinct opportunity in the new media sector and, since joining in March 2019, we have made progress establishing the offering and building out our market presence. The reception from our targeted market has been good and we are now leveraging our team's knowledge, experience and contact base to implement our strategy to create shareholder value."

 

**ENDS**

 

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

 

Shard Capital Partners LLP

Co-broker - Damon Heath, Erik Woolgar

Tel: +44 (0) 20 7186 9950

St Brides Partners Limited

PR - Melissa Hancock, Juliet Earl

Tel: +44 (0) 20 7236 1177

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKMGMNDGMGLZM
Date   Source Headline
28th Mar 20247:00 amRNSInterim Results
11th Mar 202412:00 pmRNSHeads of Terms Signed
29th Feb 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSSuspension of Trading
13th Feb 20242:08 pmRNSResult of AGM
7th Feb 20249:10 amRNSConversion of Notes and Allotment of Shares
19th Jan 20243:49 pmRNSNotice of AGM
4th Jan 20247:00 amRNSBoard Changes & Business and Strategy Update
29th Dec 20237:00 amRNSTotal Voting Rights
7th Dec 20238:53 amRNSConversion of Securities
4th Dec 20237:53 amRNSConversion of Securities
30th Nov 20237:00 amRNSTotal Voting Rights
17th Nov 202311:32 amRNSConversion of Securities
13th Nov 20238:40 amRNSConversion of Securities
2nd Nov 202310:35 amRNSConversion of Securities
31st Oct 20239:29 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSFull Year Results for the Year ended 30 June 2023
24th Oct 20235:31 pmRNSChange of Auditor
17th Oct 20237:51 amRNSConversion of Securities
13th Oct 202311:32 amRNSAnnouncement of the Completion of CVA
13th Oct 202311:30 amRNSConversion of Securities
29th Sep 20238:01 amRNSTotal Voting Rights
22nd Sep 20239:40 amRNSConversion of Securities
18th Sep 20236:27 pmRNSConversion of Notes – Replacement
18th Sep 20237:37 amRNSConversion of Securities
12th Sep 20238:45 amRNSStatement re CVA
4th Sep 202312:02 pmRNSConversion of Securities
31st Aug 20237:21 amRNSTotal Voting Rights
25th Aug 20234:49 pmRNSResult of AGM
18th Aug 20237:51 amRNSConversion of Securities
14th Aug 20237:59 amRNSIssue of Debt
8th Aug 20232:58 pmRNSPublication of a Prospectus
4th Aug 20234:19 pmRNSNotice of AGM
30th Jun 20239:12 amRNSTotal Voting Rights
2nd Jun 20231:20 pmRNSIssue of Equity
28th Apr 202310:35 amRNSTotal Voting Rights
12th Apr 20238:13 amRNSConversion of Securities
31st Mar 20233:11 pmRNSTotal Voting Rights
31st Mar 20231:59 pmRNSHalf-year Report
29th Mar 20232:05 pmRNSSecond Price Monitoring Extn
29th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Mar 20237:42 amRNSConversion of Securities
27th Mar 202311:05 amRNSSecond Price Monitoring Extn
27th Mar 202311:00 amRNSPrice Monitoring Extension
22nd Mar 202311:48 amRNSSubscription of Convertible Notes
21st Mar 202311:05 amRNSSecond Price Monitoring Extn
21st Mar 202311:00 amRNSPrice Monitoring Extension
21st Mar 20239:05 amRNSSecond Price Monitoring Extn
21st Mar 20239:00 amRNSPrice Monitoring Extension
20th Mar 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.